Five Cases of Onychatrophy Following Bleomycin Intralesional Injections for Periungual Warts.
- Author:
Tae Wook KIM
1
;
Seung Wook JWA
;
Margaret SONG
;
Hoon Soo KIM
;
Hyun Chang KO
;
Byung Soo KIM
;
Moon Bum KIM
Author Information
1. Department of Dermatology, Pusan National University School of Medicine, and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea. smargie@hanmail.net
- Publication Type:Case Report
- Keywords:
Bleomycin;
Onychatrophy;
Periungual warts
- MeSH:
Bleomycin;
Epidermolysis Bullosa;
Hemangioma;
Injections, Intralesional;
Lichen Planus;
Nails;
Paronychia;
Pemphigoid, Bullous;
Pterygium;
Raynaud Disease;
Stevens-Johnson Syndrome;
Warts
- From:Korean Journal of Dermatology
2012;50(3):262-265
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Onychatrophy is the processes in which the nail has initially formed satisfactorily and then shows total or partial regression. The causes of onychatrophy with pterygium include lichen planus, acrosclerosis, Stevens-Johnson syndrome, and cicatrical pemphigoid, and those without pterygium include severe paronychia, Stevens-Johnson syndrome, epidermolysis bullosa, and drugs. Bleomycin is an antitumor, antibacterial, and antiviral agent used in many dermatologic diseases such as warts, vascular anomalies, hemangioma, and cutaneous malignancies. Cutaneous adverse effects of bleomycin strongly depend on the route of administration and dosage. Bleomycin intralesional injection for periungual warts could result in permanent Raynaud phenomenon, nail dystrophy, and nail loss. We report five cases of onychatrophy following bleomycin intralesional injections for periungual warts. We remind that if bleomycin intralesional injection near the nail matrix is inevitable in recalcitrant periungual warts, the performer must manipulate precisely to avoid adverse effects.
